Academic Journal
Sodium-glucose cotransporter type 2 inhibitors in the treatment of chronic heart failure: new evidence ; Ингибиторы натрий-глюкозного котранспортера 2-го типа в лечении хронической сердечной недостаточности: новые доказательные данные
| العنوان: | Sodium-glucose cotransporter type 2 inhibitors in the treatment of chronic heart failure: new evidence ; Ингибиторы натрий-глюкозного котранспортера 2-го типа в лечении хронической сердечной недостаточности: новые доказательные данные |
|---|---|
| المؤلفون: | V. N. Larina, M. V. Leonova, В. Н. Ларина, М. В. Леонова |
| المصدر: | Meditsinskiy sovet = Medical Council; № 6 (2024); 187-196 ; Медицинский Совет; № 6 (2024); 187-196 ; 2658-5790 ; 2079-701X |
| بيانات النشر: | REMEDIUM GROUP Ltd. |
| سنة النشر: | 2024 |
| المجموعة: | Medical Council (E-Journal) / Медицинский Совет |
| مصطلحات موضوعية: | прогноз, left ventricular ejection fraction, sodium-glucose cotransporter type 2 inhibitors, quadruple therapy, prognosis, фракция выброса левого желудочка, ингибиторы натрий-глюкозного котранспортера-2, квадротерапия |
| الوصف: | Rational pharmacotherapy for chronic heart failure (HF) remains a relevant issue due to the unfavorable prognosis. Several major studies have confirmed the beneficial effect on reducing hospitalization rates and mortality of modern disease-modifying therapy, including sodium-glucose cotransporter type 2 inhibitors (SGLT-2 inhibitors or gliflozins), considered first-line therapy regardless of the left ventricular ejection fraction (LVEF) and diabetes mellitus in HF patients. The review presents the studied mechanisms of action of this group of drugs in HF, including metabolic, hemodynamic, and other pleiotropic effects, through which SGLT-2 inhibitors prevent the development and progression of HF with different LVEF. The possibilities of the influence of SGLT-2 inhibitors on clinical symptoms and quality of life of HF patients are discussed, as well as the change in the level of N-terminal pro-B-type natriuretic peptide as a target for rational clinical use justification. The concept of quadruple therapy, depending on the clinical situation, is presented, the basis of which is the rapid and simultaneous initiation of a combina-Rational pharmacotherapy for chronic heart failure (HF) remains a relevant issue due to the unfavorable prognosis. Several major studies have confirmed the beneficial effect on reducing hospitalization rates and mortality of modern disease-modifying therapy, including sodium-glucose cotransporter type 2 inhibitors (SGLT-2 inhibitors or gliflozins), considered first-line therapy regardless of the left ventricular ejection fraction (LVEF) and diabetes mellitus in HF patients. The review presents the studied mechanisms of action of this group of drugs in HF, including metabolic, hemodynamic, and other pleiotropic effects, through which SGLT-2 inhibitors prevent the development and progression of HF with different LVEF. The possibilities of the influence of SGLT-2 inhibitors on clinical symptoms and quality of life of HF patients are discussed, as well as the change in the level of N-terminal ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://www.med-sovet.pro/jour/article/view/8284/7305; Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. https://doi.org/10.1093/cvr/cvac013.; Шляхто ЕВ, Беленков ЮН, Бойцов СА, Виллевальде СВ, Галявич АС, Глезер МГ и др. Проспективное наблюдательное многоцентровое регистровое исследование пациентов с хронической сердечной недостаточностью в Российской Федерации (ПРИОРИТЕТ-ХСН): обоснование, цели и дизайн исследования. Российский кардиологический журнал. 2023;28(6):5456. https://doi.org/10.15829/1560-4071-2023-5456.; Gomez-Soto FM, Andrey JL, Garcia-Egido AA, Escobar MA, Romero SP, Garcia-Arjona R et al. Incidence and mortality of heart failure: a communitybased study. Int J Cardiol. 2011;151:40–45. https://doi.org/10.1016/j.ijcard.2010.04.055.; Шляхто ЕВ, Беленков ЮН, Бойцов СА, Виллевальде СВ, Галявич АС, Глезер МГ и др. Результаты промежуточного анализа проспективного наблюдательного многоцентрового регистрового исследования пациентов с хронической сердечной недостаточностью в Российской Федерации «ПРИОРИТЕТ-ХСН»: исходные характеристики и лечение первых включенных пациентов. Российский кардиологический журнал. 2023;28(10):5593. https://doi.org/10.15829/1560-4071-2023-5593.; Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816.; Gutmann C, Zelniker T, Mayr M. SGLT2 inhibitors in heart failure: insights from plasma proteomics. Eur Heart J. 2022;43(48):5003–5005. https://doi.org/10.1093/eurheartj/ehac624.; Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium– glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:422–434. https://doi.org/10.1016/J.JACC.2019.11.031.; Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632–644. https://doi.org/10.1016/j.jacbts.2020.02.004.; Dardano A, Miccoli R, Bianchi C, Daniele G, Del Prato S. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: which patients for GLP-1RA or SGLT-2 inhibitor? Diabetes Res Clin Pract. 2020;162:108112. https://doi.org/10.1016/j.diabres.2020.108112.; Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K et al. Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci. 2022;23(7):3587. https://doi.org/10.3390/ijms23073587.; Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res. 2021;117(1):74–84. https://doi.org/10.1093/cvr/cvaa064.; Caulfield MJ, Munroe PB, O’Neill D, Witkowska K, Charchar FJ, Doblado M et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5(10):e197. https://doi.org/10.1371/journal.pmed.0050197.; Паневин ТС, Елисеев МС, Бобкова АО, Димитрева АЕ, Урумова ММ. Применение дапаглифлозина у коморбидного пациента: новые возможности. Нефрология. 2023;27(2):109–115. https://doi.org/10.36485/1561-6274-2023-27-2-109-115.; Pandey AK, Bhatt DL, Pandey A, Marx N, Cosentino F, Pandey A, Verma S. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44(37):3640–3651. https://doi.org/10.1093/eurheartj/ehad389.; Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028–1039. https://doi.org/10.1161/CIRCULATIONAHA.120.045691.; Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/NEJMoa1611925.; McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303.; Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720.; Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128.; Мареев ВЮ, Фомин ИВ, Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная недостаточность. 2017;18(1):3–40. Режим доступа: https://endovascular-society.ru/download/guidelines_2/2016_CHF_rus.pdf.; Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. Available at: https://pubmed.ncbi.nlm.nih.gov/30415602.; Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205–2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255.; Marx N, Müller-Wieland D. SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world. Eur Heart J. 2023;44(24):2231–2233. https://doi.org/10.1093/eurheartj/ehad282.; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.; Агеев ФТ, Арутюнов ГП, Беграмбекова ЮЛ, Беленков ЮН, Бойцов СА, Васюк ЮА и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083.; Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757–767. https://doi.org/10.1016/S0140-6736(22)01429-5.; Fu EL, Patorno E, Everett BM, Vaduganathan M, Solomon SD, Levin R et al. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. Eur Heart J. 2023;44(24):2216–2230. https://doi.org/10.1093/eurheartj/ehad273.; Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038.; Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829. https://doi.org/10.1016/S0140-6736(20)31824-9.; Chambergo-Michilot D, Tauma-Arrué A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;32:100690. https://doi.org/10.1016/j.ijcha.2020.100690.; Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C et al. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovasc Drugs Ther. 2021;35(5):1067–1076. https://doi.org/10.1007/s10557-020-07099-2.; Ahmad Y, Madhavan MV, Stone GW, Francis DP, Makkar R, Bhatt DL, Howard JP. Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. Eur Heart J Qual Care Clin Outcomes. 2022;8(4):383–390. https://doi.org/10.1093/ehjqcco/qcab072.; Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–155. https://doi.org/10.1002/clc.23321.; Zhou Q, Li P, Zhao H, Xu X, Li S, Zhao J et al. Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?. Front Cardiovasc Med. 2021;8:678121. https://doi.org/10.3389/fcvm.2021.678121.; Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43(5):416–426. https://doi.org/10.1093/eurheartj/ehab798.; Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089–1098. https://doi.org/10.1056/NEJMoa2206286.; Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117–128. https://doi.org/10.1056/NEJMoa2030183.; Banerjee M, Pal R, Nair K, Mukhopadhyay S. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Indian Heart J. 2023;75(2):122–127. https://doi.org/10.1016/j.ihj.2023.03.003.; Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129–139. https://doi.org/10.1056/NEJMoa2030186.; Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139(22):2528–2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130.; Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967.; Xiang B, Zhang R, Wu X, Zhou X. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Metaanalysis. JAMA Netw Open. 2022;5(9):e2231963. https://doi.org/10.1001/jamanetworkopen.2022.31963.; Chen J, Jiang C, Guo M, Zeng Y, Jiang Z, Zhang D et al. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23(1):2. https://doi.org/10.1186/s12933-023-02042-9.; Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M et al. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? JACC Basic Transl Sci. 2022;7(5):504–517. https://doi.org/10.1016/j.jacbts.2021.10.018.; Голухова ЕЗ. Эксперты призывают незамедлительно начинать четырехкомпонентную терапию больным с сердечной недостаточностью и сниженной фракцией выброса левого желудочка. Креативная кардиология. 2020;14(3):201–205. https://doi.org/10.24022/1997-3187-2020-14-3-201-205.; Карпов ЮА, Пушкарева СЮ, Тхорикова ВН. «Великолепная четверка»: эффективность и влияние каждого из 4 компонентов базовой терапии и своевременности их назначения на прогноз пациентов с хронической сердечной недостаточностью. Новости кардиологии. 2022;(1):32–40. https://doi.org/10.24412/2076-4189-2022-12702.; Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive diseasemodifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–128. https://doi.org/10.1016/S0140-6736(20)30748-0.; Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73–84. https://doi.org/10.1016/j.jchf.2021.09.004.; Xiang B, Yu Z, Zhou X. Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. Front Cardiovasc Med. 2022;8:787810. https://doi.org/10.3389/fcvm.2021.787810.; Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810. https://doi.org/10.1016/j.jacc.2020.11.022.; McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021;37(4):531–546. https://doi.org/10.1016/j.cjca.2021.01.017.; Talha KM, Butler J, Greene SJ, Aggarwal R, Anker SD, Claggett BL et al. Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure. Eur J Heart Fail. 2023;25(7):999–1009. https://doi.org/10.1002/ejhf.2864.; https://www.med-sovet.pro/jour/article/view/8284 |
| DOI: | 10.21518/ms2024-129 |
| الاتاحة: | https://www.med-sovet.pro/jour/article/view/8284 https://doi.org/10.21518/ms2024-129 |
| Rights: | Authors publishing their articles in this journal shall agree to the following:Authors reserve the copyright to the work and grant the journal a license to publish the work for the first time Creative Commons Attribution License (CC BY- NC-ND), which allows other persons to distribute this work with the obligatory preservation of references to the authors of the original work and the original publication in this journal.Authors reserve the right to conclude separate contractual arrangements regarding the non-exclusive distribution of the work version in the form published here (for example, posting it in the institute’s repository, publication in a book), with reference to its original publication in this journal.Authors have the right to post work on the Internet (for example, in the institute’s repository or personal website) before and during the process of considering it by this journal, as this can result in a productive discussion and more references to this work. ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License (CC BY- NC-ND), которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию.Авторы имеют право размещать работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу. (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.B836063F |
| قاعدة البيانات: | BASE |
| DOI: | 10.21518/ms2024-129 |
|---|